Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.
Centro de Medicina Regenerativa, Facultad de Medicina, Universidad del Desarrollo, Santiago, Chile.
Addict Biol. 2021 Jan;26(1):e12853. doi: 10.1111/adb.12853. Epub 2019 Nov 15.
Chronic alcohol intake leads to neuroinflammation and cell injury, proposed to result in alterations that perpetuate alcohol intake and cued relapse. Studies show that brain oxidative stress is consistently associated with alcohol-induced neuroinflammation, and literature implies that oxidative stress and neuroinflammation perpetuate each other. In line with a self-perpetuating mechanism, it is hypothesized that inhibition of either oxidative stress or neuroinflammation could reduce chronic alcohol intake and relapse. The present study conducted on alcohol-preferring rats shows that chronic ethanol intake was inhibited by 50% to 55% by the oral administration of low doses of either the antioxidant N-acetylcysteine (40 mg/kg/d) or the anti-inflammatory aspirin (ASA; 15 mg/kg/d), while the co-administration of both dugs led to a 70% to 75% (P < .001) inhibition of chronic alcohol intake. Following chronic alcohol intake, a prolonged alcohol deprivation, and subsequent alcohol re-access, relapse drinking resulted in blood alcohol levels of 95 to 100 mg/dL in 60 minutes, which were reduced by 60% by either N-acetylcysteine or aspirin and by 85% by the co-administration of both drugs (blood alcohol: 10 to 15 mg/dL; P < .001). Alcohol intake either on the chronic phase or following deprivation and re-access led to a 50% reduction of cortical glutamate transporter GLT-1 levels, while aspirin administration fully returned GLT-1 to normal levels. N-acetylcysteine administration did not alter GLT-1 levels, while N-acetylcysteine may activate the cystine/glutamate transport xCT, presynaptically inhibiting relapse. Overall, the study suggests that a neuroinflammation/oxidative stress self-perpetuation cycle maintains chronic alcohol intake and relapse drinking. The co-administration of anti-inflammatory and antioxidant agents may have translational value in alcohol-use disorders.
慢性酒精摄入会导致神经炎症和细胞损伤,据推测这些变化会导致酒精摄入的持续和提示性的复发。研究表明,大脑氧化应激与酒精引起的神经炎症始终相关,文献表明氧化应激和神经炎症相互促进。根据自我维持机制,假设抑制氧化应激或神经炎症中的任何一种都可以减少慢性酒精摄入和复发。本研究在酒精偏好大鼠中进行,结果表明,低剂量抗氧化剂 N-乙酰半胱氨酸(40mg/kg/d)或抗炎药阿司匹林(ASA;15mg/kg/d)的口服给药可将慢性乙醇摄入抑制 50%至 55%,而两种药物的联合给药可将慢性酒精摄入抑制 70%至 75%(P<.001)。在慢性酒精摄入后,长时间的酒精剥夺和随后的酒精再摄入导致复发饮酒在 60 分钟内使血液酒精水平达到 95 至 100mg/dL,而 N-乙酰半胱氨酸或阿司匹林可使血液酒精水平降低 60%,两种药物联合给药可使血液酒精水平降低 85%(血液酒精:10 至 15mg/dL;P<.001)。无论是在慢性阶段还是在剥夺和再摄入后,酒精摄入都会使皮质谷氨酸转运体 GLT-1 水平降低 50%,而阿司匹林给药可使 GLT-1 完全恢复正常水平。N-乙酰半胱氨酸给药不会改变 GLT-1 水平,而 N-乙酰半胱氨酸可能会激活胱氨酸/谷氨酸转运体 xCT,从而抑制复发的发生。总的来说,该研究表明,神经炎症/氧化应激的自我维持循环维持了慢性酒精摄入和复发饮酒。抗炎和抗氧化剂的联合给药可能在酒精使用障碍中具有转化价值。